Acarix AB logo

Acarix AB (ACIXF)

Market Closed
7 Aug, 20:00
OTC PINK OTC PINK
$
0. 03
+0
+1.1195%
$
26.29M Market Cap
- P/E Ratio
- Div Yield
100,000 Volume
- Eps
$ 0.03
Previous Close
Add Transaction
Day Range
0.03 0.03
Year Range
0.02 0.04
Want to track ACIXF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ACIXF closed Friday higher at $0.03, an increase of 1.1195% from Thursday's close, completing a monthly decrease of -3.0471% or $0. Over the past 12 months, ACIXF stock lost -8.046%.
ACIXF is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0007%, based on the last three reports.
Acarix AB has completed 1 stock splits, with the recent split occurring on Dec 29, 2023.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XSTO (SEK).

ACIXF Chart

People also search for

Decker Manufacturing Corporation
$ 57.01
0%
Cannabix Technologies Inc.
$ 0.37
-6.775%
VicapSys Life Sciences Inc.
$ 1.45
0%
Nuo Therapeutics Inc.
$ 0.85
0%
Quantumzyme Corp.
$ 0.8
+33.3333%

Acarix AB (ACIXF) FAQ

What is the stock price today?

The current price is $0.03.

On which exchange is it traded?

Acarix AB is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is ACIXF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 26.29M.

Has Acarix AB ever had a stock split?

Acarix AB had 1 splits and the recent split was on Dec 29, 2023.

Acarix AB Profile

Health Care Technology Industry
Healthcare Sector
Aamir Mahmood CEO
OTC PINK Exchange
SE0009268717 ISIN
SE Country
8 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Acarix AB (publ) is a pioneering medical device company founded in 2009, with its headquarters situated in Malmö, Sweden. It focuses on the development of innovative solutions designed for the rapid rule-out of coronary artery disease (CAD) using advanced AI technologies. The company has established itself in the global market by offering its state-of-the-art diagnostic aids in countries across the Nordic region, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. Acarix AB leverages sensitive acoustics and sophisticated computational processing to enhance the accuracy and efficiency of CAD diagnosis, aiming to improve patient outcomes and streamline healthcare processes.

Products and Services

  • CADScor System
  • This innovative point-of-care diagnostic aid is at the forefront of Acarix AB's product lineup. The CADScor System utilizes the company's groundbreaking technology to analyze the acoustics of coronary blood flow, combined with advanced computational processing. Its primary use is in the rapid rule-out of coronary artery disease (CAD), offering clinicians a non-invasive, highly sensitive tool for assessing patients. By employing this system, healthcare practitioners can quickly identify patients who may need further cardiovascular diagnostic assessments, thereby optimizing the care pathway and reducing unnecessary hospital referrals and diagnostics.

Contact Information

Address: World Trade Center
Phone: +45 44 41 44 41